As Senior Vice President, Immunometabolism, Andy brings over 25 years of drug development experience to Rheos. Prior to Rheos, Andy spent 13 years in Immunology Discovery at AbbVie where he was involved in the development and launch of RINVOQ, a JAK1 selective inhibitor for the treatment of rheumatoid arthritis. He also led discovery effort to deliver multiple small molecule programs into clinical development for the treatment of autoimmune diseases. Prior to AbbVie, Andy spent 15 years at the Genetics Institute and Wyeth, where he was involved in the discovery and characterization of the cognate ligands for PD-1. This work was highlighted as a key publication for the 2018 Nobel Prize in Medicine.
Andy earned his Ph.D. in Pharmacology from Boston University School of Medicine and his B.S. in Biological Sciences from the University of Vermont.